Hussman Strategic Advisors Lowers stake in Eli Lilly and Co (LLY)

Eli Lilly and Co (LLY) : Hussman Strategic Advisors reduced its stake in Eli Lilly and Co by 60.0% during the most recent quarter end. The investment management company now holds a total of 50,000 shares of Eli Lilly and Co which is valued at $4,136,000 after selling 75,000 shares in Eli Lilly and Co , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.Eli Lilly and Co makes up approximately 0.61% of Hussman Strategic Advisors’s portfolio.

Other Hedge Funds, Including , Spinnaker Trust added LLY to its portfolio by purchasing 2,690 company shares during the most recent quarter which is valued at $222,517. Eli Lilly and Co makes up approx 0.03% of Spinnaker Trust’s portfolio.Bollard Group boosted its stake in LLY in the latest quarter, The investment management firm added 1,066 additional shares and now holds a total of 301,986 shares of Eli Lilly and Co which is valued at $24,639,038. Eli Lilly and Co makes up approx 1.66% of Bollard Group’s portfolio.Balasa Dinverno Foltz reduced its stake in LLY by selling 481 shares or 13.75% in the most recent quarter. The Hedge Fund company now holds 3,017 shares of LLY which is valued at $241,209. Eli Lilly and Co makes up approx 0.04% of Balasa Dinverno Foltz’s portfolio.Fisher Asset Management boosted its stake in LLY in the latest quarter, The investment management firm added 238,524 additional shares and now holds a total of 1,984,912 shares of Eli Lilly and Co which is valued at $157,522,616. Eli Lilly and Co makes up approx 0.30% of Fisher Asset Management’s portfolio.

Eli Lilly and Co closed down -0.3 points or -0.36% at $82.42 with 20,93,793 shares getting traded on Thursday. Post opening the session at $83.02, the shares hit an intraday low of $82.37 and an intraday high of $83.02 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.

Investors should note that on Jun 20, 2016, Eli Lilly and Co announced a cash dividend of $0.5100. The company’s management has announced Aug 11, 2016 as the ex-dividend date and fixed the record date on Aug 15, 2016. The payable date has been fixed on Sep 9, 2016.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.

Leave a Reply

Eli Lilly and Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Eli Lilly and Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.